AnaptysBio, Inc. (ANAB) financial statements (2020 and earlier)

Company profile

Business Address 10421 PACIFIC CENTER COURT, SUITE 200
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments421427248
Cash and cash equivalents18311481
Short-term investments238313167
Other undisclosed current assets474
Total current assets:425434253
Noncurrent Assets
Property, plant and equipment211
Long-term investments and receivables237376
Long-term investments237376
Deposits noncurrent assets  0
Restricted cash and investments000
Other noncurrent assets20 
Total noncurrent assets:277577
TOTAL ASSETS:452509329
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities26147
Accounts payable1152
Accrued liabilities1595
Debt387
Other liabilities100
Total current liabilities:302214
Noncurrent Liabilities
Long-term debt and lease obligation 18
Long-term debt, excluding current maturities 18
Liabilities, other than long-term debt100
Accounts payable and accrued liabilities 00
Other liabilities1  
Total noncurrent liabilities:118
Total liabilities:312322
Stockholders' equity
Stockholders' equity attributable to parent421486308
Common stock000
Additional paid in capital644633393
Accumulated other comprehensive income (loss)0(0)(0)
Accumulated deficit(224)(147)(85)
Total stockholders' equity:421486308
TOTAL LIABILITIES AND EQUITY:452509329

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Revenue, net10
Gross profit:5510
Operating expenses(110)(72)(39)
Operating loss:(105)(67)(29)
Nonoperating income (expense)105(1)
Investment income, nonoperating  2
Other nonoperating income (expense)0(0)0
Interest and debt expense(1)(2)(2)
Other undisclosed income from continuing operations before equity method investments, income taxes1  
Loss from continuing operations before equity method investments, income taxes:(95)(64)(32)
Other undisclosed income from continuing operations before income taxes222
Loss from continuing operations before income taxes:(93)(62)(30)
Income tax benefit00 
Other undisclosed income from continuing operations0  
Net loss:(93)(62)(30)
Other undisclosed net loss attributable to parent(1)  
Net loss available to common stockholders, diluted:(94)(62)(30)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss:(93)(62)(30)
Other comprehensive income (loss)10(0)
Other undisclosed comprehensive income0  
Comprehensive loss:(92)(61)(30)
Other undisclosed comprehensive loss, net of tax, attributable to parent(1)  
Comprehensive loss, net of tax, attributable to parent:(93)(61)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: